Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00055) | |||||
---|---|---|---|---|---|
Name |
Azilsartan medoxomil
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
863031-21-4; Edarbi; TAK 491; TAK-491; UNII-LL0G25K7I2; LL0G25K7I2; CHEBI:68845; 863031-21-4 (free acid); 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]Methyl]-2-ethoxy-1H-benziMidazole-7-carboxylic acid (5-Methyl-2-oxo-1,3-dioxol-4-yl)Methyl ester; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylate; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1-benzimidazole-7-carboxylate; Azilsartan medoxomil [USAN:INN]; C30H24N4O8; azilsartan medoxomilo; Azilsartan (medoxomil); azilsartanum medoxomilum; Azilsartan TAK-536; Azilsartan medoxomil (USAN); cc-351; SCHEMBL683374; GTPL6900; CHEMBL2028661; DTXSID10235482; Azilsartan Medoxomil (TAK-491); HMS3651H18; BCP03898; MFCD19443688; ZINC14210642; AKOS007930700; CCG-270084; CS-1369; DB08822; SB19560; AK-68150; AS-57282; HY-14736; FT-0689999; SW219494-1; A16420; D08067; W-5816; AB01566809_01; Q1087888; W-203965; S900005850; (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-((2'-(5-oxo-4,5-dihydro-1,2,4- oxadiazol-3-yl)biphenyl-2-yl)methyl)-1H-benzo(d)imidazole-7-carboxylate; (5-Methyl-2-Oxo-1,3-Dioxol-4-Yl)Methyl 2-Ethoxy-1-{[2'-(5-Oxo-4,5-Dihydro-1,2,4-Oxadiazol-3 -Yl)Biphenyl-4-Yl]Methyl}-1H-Benzimidazole-7-Carboxylate; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-2H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-+oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate; 1-[[2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester1H- Benzimidazole-7-carboxylic acid; 1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl; 1H-Benzimidazole-7-carboxylic acid, 1-((2'-(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl)(1,1'-biphenyl)-4-yl)methyl)-2-ethoxy-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester; 2-Ethoxy-1-[[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazole-3-yl)-4-biphenylyl]methyl]-1H-benzoimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxole-4-yl)methyl ester
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Essential hypertension | ICD-11: BA00 | [1] | ||
PubChem CID | |||||
Formula |
C30H24N4O8
|
||||
Canonical SMILES |
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NOC(=O)N5)C(=O)OCC6=C(OC(=O)O6)C
|
||||
InChI |
1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)
|
||||
InChIKey |
QJFSABGVXDWMIW-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=135409642"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 568.5 | Topological Polar Surface Area | 140 | |
XlogP | 4.9 | Complexity | 1100 | ||
Heavy Atom Count | 42 | Rotatable Bond Count | 10 | ||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 10 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Azilsartan medoxomil 40 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Fumaric acid; Magnesium stearate; Mannitol; Sodium hydroxide; Croscarmellose sodium; Hydroxypropyl cellulose (1200000 mw); Microcrystalline cellulose
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Arbor Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Fumaric acid; Magnesium stearate; Mannitol; Sodium hydroxide; Croscarmellose sodium; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Takeda Pharmaceuticals America | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Azilsartan medoxomil 80 mg tablet | Click to Show/Hide the Full List of Formulation(s): 2 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Fumaric acid; Magnesium stearate; Mannitol; Sodium hydroxide; Croscarmellose sodium; Hydroxypropyl cellulose (1200000 mw); Microcrystalline cellulose
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Arbor Pharmaceuticals | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
Drug Formulation 2 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Fumaric acid; Magnesium stearate; Mannitol; Sodium hydroxide; Croscarmellose sodium; Cellulose, microcrystalline; Hydroxypropyl cellulose (type h)
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Takeda Pharmaceuticals America | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Mannitol | DIG Info | Glycine receptor alpha-1 (EC50 = 12589.25 nM) | [2] | |||
Fumaric acid | DIG Info | HIF-prolyl hydroxylase 2 (IC50 = 19000 nM) | [3] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [4] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [4] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.